tofersen ALS
Selected indexed studies
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (N Engl J Med, 2022) [PMID:36129998]
- Tofersen for SOD1 ALS. (Neurodegener Dis Manag, 2024) [PMID:39330700]
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (N Engl J Med, 2020) [PMID:32640130]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tofersen for SOD1 ALS. (2024) pubmed
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (2022) pubmed
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. (2020) pubmed
- Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients. (2024) pubmed
- Tofersen and other antisense oligonucleotides in ALS. (2025) pubmed
- Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting. (2025) pubmed
- Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS. (2024) pubmed
- Tofersen (Qalsody) for ALS. (2023) pubmed
- Effects of tofersen treatment in patients with SOD1-ALS in a "real-world" setting - a 12-month multicenter cohort study from the German early access program. (2024) pubmed
- Disease Modification in SOD1-ALS With Tofersen May Result in Serious CNS Inflammation. (2025) pubmed